Zura Bio (ZURA): 3-year performance

Zura Bio, the clinical-stage immunology company entered the public markets on March 21, 2023, by completing a reverse merger with the special purpose acquisition company (SPAC) JATT Acquisition Corp.

 

Zura Bio develops therapeutic medicines for immune and inflammatory disorders, with a pipeline that includes product candidates like tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880).

• Founded 2022
• Website zurabio.com
• Employees 40
• https://zurabio.com/

IPO: March 21, 2023

Legend Biotech (LEGN) prices offering of 7.7 mln ADSs at $29.35 per ADS

• Legend Biotech prices 7.7 million ADS underwritten offering at $29.35 each for expected gross proceeds of approximately $226 million
•  Legend Biotech (NASDAQ: LEGN) went public on June 5, 2020, raising approximately $424 million in its initial public offering (IPO). The company originally offered 18.4 million American Depositary Shares (ADS) at a price of $23.00 per share.
• https://legendbiotech.com/

==Parabilis Medicines (PBLS) began trading on the Nasdaq on Wed 10 June 26

Parabilis Medicines is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them.  

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 145
• Founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 
• Formerly known as Fog Pharma
• Headquartered in Cambridge, Massachusetts
• https://parabilismed.com/

Polaryx Therapeutics (PLYX) : 3-week performance

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 11
• Founded by Hahn-Jun Lee in 2014 
• HQ: Paramus, New Jersey
• https://polaryx.com

The company focuses on developing patient-friendly, orally available small molecule therapies (and some gene therapy candidates) for rare pediatric lysosomal storage disorders (LSDs), such as neuronal ceroid lipofuscinosis (e.g., CLN2, CLN3), Krabbe disease, Sandhoff disease, and others.

• Lead Candidate: PLX-200 (a repurposed oral small molecule, e.g., based on gemfibrozil) targets multiple LSDs by promoting lysosome biogenesis, reducing inflammation, and protecting neuronal function.
• Pipeline: Includes PLX-100, PLX-300 (preclinical combinations), and PLX-400 (preclinical gene therapy).

AgomAb Therapeutics NV (AGMB) began trading on the Nasdaq on Fri 6 Feb 26

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 57
• Incorporated in 2017 
• Headquartered in Antwerp, Belgium
• https://agomab.com

AgomAb Therapeutics NV opened at $14.70 after pricing a 12.5 mln share IPO at $16.00 per ADS, at the midpoint of the $15-17 expected range

 

SpyGlass Pharma (SGP) began trading on the Nasdaq on Fri 6 Feb 26

SpyGlass Pharma opened at $24 after pricing a 9.375 mln share IPO at $16.00 per share, at the midpoint of the $15-17 expected range

• SpyGlass Pharma (SGP) roared onto the public markets today, as its IPO of 9.375 mln shares priced at the $16 midpoint of its $15-$17 range, opened for trading at $24 (a 50% gain), and is currently trading near $29.
• The company's lead product candidate, the Bimatoprost Drug Pad-IOL System, targets the $13 bln glaucoma market by attaching drug-eluting pads to an intraocular lens implanted during routine cataract surgery, delivering three years of medication to solve the critical issue of patient non-adherence to daily drops.
• While SGP remains pre-revenue with a net loss of $27.3 mln for the first nine months of 2025, its growth strategy relies on leveraging a known drug (bimatoprost) and a standard surgical procedure to pursue a streamlined regulatory pathway.
• Beyond its lead asset, the company is advancing a "Drug Ring System" for standalone procedures, positioning its proprietary platform as a versatile, lifetime solution for chronic eye conditions.
• The enthusiastic investor reception reflects high confidence in a technology that integrates seamlessly into the existing cataract workflow without requiring surgeons to learn complex new techniques.
• Ultimately, the market is pricing in a "de-risked" commercialization path, supported by the company's plan to utilize existing CPT reimbursement codes to align provider economics with improved patient outcomes.
• SpyGlass, based in California, is making drug-device combinations for ocular conditions. One program is a lens implanted during cataract surgery. With the help of attached drug pads, it’s meant to treat glaucoma and ocular hypertension by slowly releasing a medication that lowers eye pressure. The therapy, codenamed BIM-IOL, is currently in two Phase 3 studies that started last month. SpyGlass expects to complete enrollment in 2027.

SpyGlass Pharma is a biopharmaceutical company focused on developing sustained drug delivery systems for chronic eye diseases, particularly glaucoma. Their approach uses a proprietary non-bioerodible platform to deliver medications long-term, often integrated with existing procedures like cataract surgery.Their main drug candidates, based on their pipeline and recent clinical advancements (as of early 2026), are:

• BIM-IOL System (Bimatoprost Drug Pad-Intraocular Lens System): This is their lead product candidate. It involves proprietary non-bioerodible drug pads attached to a monofocal intraocular lens (IOL), implanted during routine cataract surgery. It delivers bimatoprost (a prostaglandin analog) sustained over up to 3 years to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
  • It is in Phase III development, with two registrational trials (SGP-005 and SGP-006) having started randomization in January 2026.
  • Earlier trials (including 36-month first-in-human data) showed positive results, such as ~37% mean IOP reduction and safety comparable to standard cataract surgery.
• BIM-DRS (Bimatoprost Drug Ring System): This is their next-generation sustained-release implant. It is a removable and replaceable ring-shaped device for multi-year drug delivery (also bimatoprost). It targets a broader glaucoma population (including those not undergoing cataract surgery) and enables retreatment for patients previously treated with the BIM-IOL System. It has potential for lifelong disease management.
  • It is earlier in development, with first-in-human studies planned for 2026.

The company's platform is designed to be flexible for other approved medications and conditions (e.g., front/back of the eye diseases), with early/preclinical mentions of potential applications like postoperative steroids, NSAIDs, chronic uveitis, or age-related macular degeneration. However, the primary focus and most advanced candidates center on the bimatoprost-based systems for glaucoma.

Eikon Therapeutics (EIKN) began trading on the Nasdaq on Thur 5 Feb 26

• Sector: HealthcareIndustry: Biotechnology
• Incorporated in 2019 
• HQ in Millbrae, California
• https://www.eikontx.com/

Eikon Therapeutics priced 21,177,600 share IPO (upgraded from 17.7 mln prior) at $18.00 per share, at the high end of the $16-18 expected range

Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024

Ticker: EIKN

At $381 million, Eikon looks set to be the largest biotech IPO since 2024, overtaking Aktis Oncology’s $318 million offering last month.

The California-based company has already set out its plans for spending the proceeds, with the biggest priority labeled as the clinical development of EIK1001. The toll-like receptor 7 and 8 agonist immune modulator, which Eikon acquired from Seven and Eight Biopharmaceuticals, is currently being tested in a phase 2/3 trial in combination with Keytruda for advanced melanoma and a phase 2/3 study for non-small cell lung cancer.

Behind EIK1001 is a pair of PARP1 inhibitors, dubbed EIK1003 and EIK1004, which Eikon licensed from Chinese biotech Impact Therapeutics. These candidates are being trialed in phase 1/2 studies for ovarian, breast, prostate and pancreatic cancers, with EIK1004 also being assessed against brain metastases and primary brain malignancies due to its ability to cross the blood-brain barrier.

The fourth clinical candidate is an in-house WRN helicase inhibitor called EIK1005, which is in phase 1/2 development for solid tumors.

Climb Bio (CLYM) : 4-year performance

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 28
Incorporated in 2018 
Headquartered in Wellesley Hills, Massachusetts
https://climbbio.com

RA Capital exchange agreement ignited multi-day rally extending into 27% gain today.

• The stock's sharp rise stems from a December 11, 2025, exchange agreement with RA Capital Management, where the investor swapped 20.44 million common shares for pre-funded warrants exercisable at a nominal price, signaling strong backing without immediate dilution. This filing, reported via SEC Form 8-K, triggered a 30.43% jump on December 12, with momentum building over subsequent days amid high volume exceeding 8 million shares. Today's movement amplifies this, as traders react to the deal's implications for sustained funding through 2027 and upcoming 2026 clinical readouts for budoprutug and CLYM116 in immune diseases, per recent analyst coverage. No new filings emerged today, but the prior event's positive sentiment persists.

Kymera Therapeutics (KYMR) : atopic dermatitis potential matches Sanofi/Regeneron's blockbuster Dupixent in early biomarker response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.

The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 208
• Founded by Bruce Lee Booth and Nello Mainolfi in September 2015 
• Headquartered in Watertown, Massachusetts
• https://www.kymeratx.com

IPO: Aug 21, 20

 

 

 

 

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. 

ADMA Biologics (ADMA)

ADMA Biologics makes human-derived immunoglobulin. Its products treat people whose bodies don't make enough antibodies to ward off illnesses from common viruses. Instead of risking illness, people with primary immunodeficiency receive regular infusions of ADMA's drugs.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 685
• Founded by Adam S. Grossman and Jerrold B. Grossman in 2004  
• Headquartered in Ramsey, New Jersey
• https://www.admabiologics.com/

IPO: October 17, 2013

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. 

ADMA's biggest moneymaker, Asceniv. 

ADMA Biologics developed Asceniv in-house. It's a cocktail created from super donors whose plasma has a high level of antibodies capable of handling respiratory syncytial virus, or RSV. RSV leads to cold symptoms in most people, but it can be serious in people with compromised immune systems.

Last year, Asceniv generated $216.7 million in sales. This year, it's expected to bring in $283 million, growing almost 31%. Earnings are also promising. In 2024, ADMA Biologics earned 49 cents per share, flipping from no earnings in the year-earlier period. This year, it's expected to notch a 71-cent profit, up 45%.

Asceniv accounts for slightly more than half of ADMA's total sales. The company also sells Bivigam and Nabi-HB, two products it acquired. Bivigam provides various antibodies found in a healthy immune system, while Nabi-HB protects against hepatitis B in people who've been exposed.

 

MeiraGTx (MGTX) $200M deal with Hologen AI for Parkinson's therapy

 

 

 

 

 

 

IPO: June 8, 2018

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond

MeiraGTx will partner with Hologen AI to leverage its multimodal generative AI (genAI) models to accelerate Phase III development of the biotech's AAV-GAD gene therapy for Parkinson’s disease. 

The therapy, dubbed AAV-GAD, delivers a gene that codes for the enzyme that makes the neurotransmitter GABA, which is implicated in the characteristic motor dysfunction of Parkinson’s. A small-scale phase 2 readout last October showed that AAV-GAD was able to improve patients' motor ability and quality of life.

Details of the agreement 

MeiraGTx will receive an upfront cash payment of $200 million from Hologen, and together, the partners will launch a joint venture called Hologen Neuro AI. The genAI firm will also contribute $230 million in funding for the JV, which will shepherd AAV-GAD through development to commercialisation. The capital will help support other early-stage clinical programmes targeting the central nervous system (CNS), such as AAV-BDNF for genetic obesity. 

MeiraGTx will retain 30% ownership in Hologen Neuro AI and take the lead on all clinical development and manufacturing. It will form exclusive clinical and commercial manufacturing supply agreements with the JV. 

In turn, Hologen will use its genAI tech to optimise MeiraGTx's manufacturing practices, while gaining a minority stake in the manufacturing subsidiary and contributing to annual funding. 

About Hologen 

Hologen Limited is a world-leading developer of generative AI capabilities for clinical medicine and pharmaceutical drug development. 

The company emerged as a spin-out from University College London and Kings College London. It is privately held.

For more information, please visit www.hologen.ai